NasdaqHealth CareHealth Care EquipmentS&P SmallCap 600
$7.33
-0.08 (-1.08%)
Close of Nov 06, 2026 · end-of-day data
AHCO 8-K filings in 2026
Every material Form 8-K AdaptHealth filed with the SEC in 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
AdaptHealth reported third-quarter 2026 net revenue of $745.6 million, up 10.9% from a year earlier, but a $184.8 million pre-tax goodwill write-down produced a net loss. The company raised its full-year 2026 revenue and Adjusted EBITDA guidance but lowered its free cash flow guidance, and it cleared the Hart-Scott-Rodino waiting period for the pending $235.0 million sale of its Diabetes Health business.
Q3 net revenue $745.6 million vs. $672.4 million; organic revenue growth of 12.8%
Q3 Adjusted EBITDA $141.9 million vs. $146.1 million, down 2.9%
2026 guidance: revenue raised to $2.88-$2.90 billion; Adjusted EBITDA raised to $510-$525 million; free cash flow cut to $50-$75 million from $80-$120 million
Diabetes Health sale for $235.0 million in cash expected to close in early 2027
AdaptHealth appointed Harriss Currie as Chief Financial Officer, effective September 9, 2026. Jason Clemens, the current CFO, ends his CFO authority on September 8, 2026, and leaves the company effective October 1, 2026, with severance for a termination without cause. The change in the top finance role is a leadership transition; the filing contains no financial results or guidance.
Harriss Currie, age 64, starts as CFO on September 9, 2026, under an employment agreement dated September 7, 2026.
Currie's annual base salary is $670,000, with a target bonus of 100% of base salary, and a sign-on RSU grant valued at $818,462.
Currie previously served as CFO of Luminex Corp. from October 2003 until its sale to DiaSorin in July 2021.
Jason Clemens's CFO authority ends September 8, 2026, and his employment ends October 1, 2026; he will receive severance for a termination without cause.
AdaptHealth reported second-quarter 2026 net revenue of $740.3 million, up 12.7% from a year earlier, but recorded a $144.2 million goodwill impairment and a net loss attributable to the company. The company also lowered its fiscal 2026 adjusted EBITDA guidance to $490 million to $520 million from $680 million to $730 million, citing a West Coast capitated contract, a manufacturer price increase and portfolio changes, which weighs on shareholders' earnings outlook.
Q2 net revenue was $740.3 million versus $657.1 million, an increase of 12.7%; organic revenue grew 15.9%.
Goodwill impairment of $144.2 million drove a net loss; adjusted EBITDA was $132.0 million versus $136.4 million, down 3.2%.
Fiscal 2026 adjusted EBITDA guidance is $490 million to $520 million; the revision includes a $100 million impact from the Diabetes Health discontinued operations, a $55 million West Coast contract impact and a $30 million manufacturer pric
AdaptHealth agreed in July 2026 to sell its Diabetes Health business for $235.0 million in cash, subject to customary purchase price adjustments.
AdaptHealth agreed on July 19, 2026 to sell substantially all assets of its Diabetes Health business to RGH Enterprises, a subsidiary of Cardinal Health, for $235.0 million in cash, subject to a working capital adjustment. The company says the sale lets it redeploy capital to core sleep and respiratory businesses and reduce debt, but it has not yet disclosed the financial effect, which it will cover on its August 4, 2026 earnings call.
Purchase price is $235.0 million in cash, with $8.0 million and $18.8 million placed in escrow at closing for price adjustment and indemnification obligations
Closing requires Hart-Scott-Rodino antitrust clearance and other customary conditions; either party may terminate if closing has not occurred within twelve months, and a $9.4 million termination fee applies in certain antitrust failure case
AdaptHealth agreed to a four-year non-compete in North America following closing
Company will discuss financial and guidance effects, including discontinued operations treatment, on its Q2 2026 earnings call on August 4, 2026
AdaptHealth said a threat actor gained unauthorized access to certain cloud-based business applications, including patient management and document storage systems, and exfiltrated some data. The company determined on June 27, 2026 that the incident is material, and said it has contained the threat and that operations and patient service have not been materially affected. The full financial impact, data scope and volume remain undetermined, and the company says cybersecurity insurance may cover some losses.
Threat actor contacted the company on June 15, 2026, claiming to have obtained data from its systems
Affected data includes insurance billing passwords and certain patient personally identifiable and protected health information
Company does not collect Social Security numbers or store financial account or payment card data in the affected systems
Company says it cannot yet determine the full financial impact and will amend the filing as information becomes available
AdaptHealth reported first-quarter 2026 net revenue of $819.8 million, up 5.4%, and raised its full-year 2026 net revenue guidance by $10 million. Net loss attributable to the company widened to $16.0 million from $7.2 million, and Adjusted EBITDA fell 5.3% to $121.2 million, so revenue gains came with lower profitability. The company also replaced its Chief Operating Officer.
Q1 2026 net revenue $819.8 million vs. $777.9 million; organic revenue growth 9.1%
Net loss attributable to AdaptHealth $16.0 million (diluted EPS -$0.12) vs. $7.2 million (-$0.05)
Adjusted EBITDA $121.2 million vs. $127.9 million; free cash flow negative $27.5 million
FY2026 net revenue guidance raised to $3.45 billion-$3.52 billion; Adjusted EBITDA ($680 million-$730 million) and free cash flow ($175 million-$225 million) guidance maintained
AdaptHealth and its subsidiary AdaptHealth LLC entered a credit agreement dated April 10, 2026, with Bank of America as administrative agent, and used it to repay the prior credit agreement from January 20, 2021. The new facility provides $450 million of revolving commitments, $325 million of initial term loans and $325 million of delayed draw term loans, and matures in April 2031. The company says the new terms carry lower pricing, and it does not expect the transaction to affect its full-year 2026 guidance.
Facility includes $450 million in revolving commitments, $325 million in initial term loans and $325 million in delayed draw term loans available for up to two years after closing.
Credit agreement dated April 10, 2026; scheduled maturity April 13, 2031, subject to a springing maturity 91 days before the 2028 Senior Notes mature if more than $15 million remains outstanding.
Proceeds repaid the prior credit agreement with Regions Bank; the company says the lowest pricing tier fell from 1.50% to 1.125% over SOFR.
The company does not expect the transaction to affect full-year 2026 guidance issued February 24, 2026.
AdaptHealth reported fourth-quarter 2025 net revenue of $846.3 million, down 1.2%, and a net loss attributable to the company of $102.8 million, compared with net income of $50.3 million a year earlier. The loss includes a non-cash goodwill impairment charge of $128.0 million, and Adjusted EBITDA fell 18.7% to $163.1 million. The company also issued 2026 guidance of $3.44 billion to $3.51 billion in net revenue and $680 million to $730 million in Adjusted EBITDA.
Q4 2025 net revenue was $846.3 million, down from $856.6 million; Adjusted EBITDA was $163.1 million, down from $200.6 million.
Q4 2025 net loss attributable to AdaptHealth was $102.8 million, including a $128.0 million non-cash goodwill impairment tied to the Diabetes Health unit.
Full-year 2025 net loss attributable to AdaptHealth was $70.8 million, versus net income of $90.4 million in 2024.
2026 guidance: net revenue of $3.44 billion to $3.51 billion, Adjusted EBITDA of $680 million to $730 million, and free cash flow of $175 million to $225 million.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every AdaptHealth filing is on SEC EDGAR ↗. 8-K briefs of other companies →